一种代谢稳定的阿佩林-13类似物,作为一种强大的ITo电流阻断剂,对布鲁加达综合征有潜在的益处
Juan Antonio Contreras Vite1, Alexandria Tiffinger1, Léa Théroux1
1Institute of Pharmacology of Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
International journal of molecular sciences
|March 27, 2025
概括
一种新型的阿佩林衍生物,2Nal,选择性地阻断了短暂的 (ITO) 电流,延长了心脏动作潜力的持续时间. 这一发现通过恢复电流平衡,为布鲁加达综合征等心律失常提供了潜在的新疗法.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿佩林是APJ受体的内源性连接体,增强心脏收缩性.
- 阿佩林在体内半衰期短,限制了其临床使用.
- 对于治疗应用,需要代谢稳定的APJ受体激动剂.
研究的目的:
- 为了研究一个修饰的apelin-13-2Nal衍生物 (2Nal) 对心脏动作潜力的动态的影响.
- 确定2Nal对大鼠心肌细胞中的快速 (INa) 和短暂 (ITO) 电流的影响.
- 评估2Nal作为治疗心律失常的治疗剂的潜力.
主要方法:
- 补丁技术被用来研究老鼠心肌细胞中的离子电流.
- 记录和分析了行动潜力的动态.
- 进行了剂量反应分析,以确定2Nal在ITO封锁上的强度和有效性.
主要成果:
- 2Nal通过阻断ITO.选择性地延长心室动作潜力的持续时间.
- 2Nal作为ITO的部分抗剂,其最大阻断率为47% (EC50 = 0.3nM).
- 2Nal没有影响INa电流,表明有选择性的作用机制.
结论:
- 2Nal选择性地阻断ITO,有助于恢复ITO和INa电流之间的平衡.
- 这种选择性阻塞可以防止与布鲁加达综合征等疾病相关的心律失常.
- 2Nal代表了一种新的,安全的部分对抗ITO,具有潜在的治疗益处.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
388
相关概念视频
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
